CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
31 mm GORE EXCLUDER® AAA Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00615069
NCT00615069Phase 2Completed
CompareCT.gov

A Clinical Study Evaluating the Use of the GORE EXCLUDER® AAA Endoprosthesis - 31mm In the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms

W.L.Gore & Associates·interventional·Posted Feb 14, 2008·Updated Apr 14, 2015

In Brief

A Phase 2 clinical trial evaluating 31 mm GORE EXCLUDER® AAA Endoprosthesis for Aortic Aneurysm, Abdominal. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of the 31 mm GORE EXCLUDER® AAA Endoprosthesis in the treatment of infrarenal abdominal aortic aneurysms

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Aneurysm, Abdominal
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 14, 2008
Enrollment StartMay 1, 2006
Primary CompletionMar 1, 2008
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.4 years ago

Interventions

31 mm GORE EXCLUDER® AAA Endoprosthesisdevice

GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)